H. Lundbeck A/S (Lundbeck) strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu AE04621
The study is to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. The placebo-controlled study is expected to enrol around 100 healthy individuals.
Lu AE04621 is a novel agent that acts on the areas of the brain that are affected in Parkinson’s disease with similar net effect as Lu 02-750, which entered phase I in November 2009. In animal models, the compound has demonstrated very convincing effects when compared to conventional treatments. Expectations are that the compound can offer Parkinson’s patients a new and higher level of disease control.
“Our focus at Lundbeck Research is on discovering new innovative treatments that address unmet needs and offer clear benefits to the patients, and we believe that Lu AE04621 has the potential to improve the treatment and quality of life of patients suffering from Parkinson’s disease”, says Executive Vice President Peter H¸ngaard Andersen, Head of Research at Lundbeck, and continues: “The parallel testing in humans of Lu 02-750 and Lu AE04621 will enable us to select the most promising compound for further development at an early stage.”
